Article

Sting Pathway Activation by Orally Administered Attenuated dsRNA Vaccine Virus for Therapy of Viral Diseases

2023-12-21

Abstract excerpt

Even after the Coronavirus disease 2019 (COVID-19) pandemic, the world's vaccine strategy is failing because vaccines are produced only after an epidemic is under way. This article argues that vaccination alone will not be sufficient to control COVID-19 or any other future pandemic (e.g., flu). Using non-pathogenic viruses to control unrelated ongoing infections could complement vaccination efforts. The attenuated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 410ffcd9-f96c-576b-8c54-a305cebce375
DOI: 10.32388/s7smjs

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Sting Pathway Activation by Orally Administered Attenuated dsRNA Vaccine Virus for Therapy of Viral DiseasesDOI 10.32388/s7smjsRead

A Harmless Avian Vaccine Virus Could Be Developed into an Off-the-Shelf “Antibiotic” for VirusesSemantic proximity Read

The clinically validated viral superinfection therapy (SIT) platform technology could cure early cases of COVID-19 diseaseSemantic proximity Read

An intranasal nanoparticle STING agonist has broad protective immunity against respiratory viruses and variantsSemantic proximity Read

A small molecule RIG-I agonist serves to adjuvant broad multifaceted influenza virus vaccine immunitySemantic proximity Read

Enhanced attenuation of chikungunya vaccines expressing antiviral cytokinesSemantic proximity Read

Repurposing NASVAC, a hepatitis B therapeutic vaccine, for pre- and postexposure prophylaxis of SARS-CoV-2 infectionSemantic proximity Read

A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis – ICE COVIDSemantic proximity Read

Emerging Alphaviruses Are Sensitive to Cellular States Induced by a Novel Small-Molecule Agonist of the STING PathwaySemantic proximity Read

Chikungunya virus vaccine candidate incorporating synergistic mutations is attenuated and protects against virulent virus challengeSemantic proximity Read

Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging AlphavirusesSemantic proximity Read

Infectious RNA vaccine protects mice against chikungunya virus infection.Semantic proximity Read

100 Day Vaccine Development–An Alternative Approach Boosters for Phase III Trialed Viral Family VaccinesSemantic proximity Read